445 related articles for article (PubMed ID: 24412416)
41. Posterior lumbar interbody fusion using recombinant human bone morphogenetic protein type 2 with cylindrical interbody cages.
Haid RW; Branch CL; Alexander JT; Burkus JK
Spine J; 2004; 4(5):527-38; discussion 538-9. PubMed ID: 15363423
[TBL] [Abstract][Full Text] [Related]
42. Comparison of TLIF with rhBMP-2 versus no TLIF and higher posterolateral rhBMP-2 dose at L5-S1 for long fusions to the sacrum with sacropelvic fixation in patients with primary adult deformity.
Rahman RK; Buchowski JM; Stephens B; Dorward IG; Koester LA; Bridwell KH
Spine (Phila Pa 1976); 2013 Dec; 38(26):2264-71. PubMed ID: 24108280
[TBL] [Abstract][Full Text] [Related]
43. Complications associated with single-level transforaminal lumbar interbody fusion.
Rihn JA; Patel R; Makda J; Hong J; Anderson DG; Vaccaro AR; Hilibrand AS; Albert TJ
Spine J; 2009 Aug; 9(8):623-9. PubMed ID: 19482519
[TBL] [Abstract][Full Text] [Related]
44. Bone Morphogenetic Proteins in Spinal Surgery: What Is the Fusion Rate and Do They Cause Cancer?
Malham GM; Giles GG; Milne RL; Blecher CM; Brazenor GA
Spine (Phila Pa 1976); 2015 Nov; 40(22):1737-42. PubMed ID: 26730525
[TBL] [Abstract][Full Text] [Related]
45. Increased swelling complications associated with off-label usage of rhBMP-2 in the anterior cervical spine.
Smucker JD; Rhee JM; Singh K; Yoon ST; Heller JG
Spine (Phila Pa 1976); 2006 Nov; 31(24):2813-9. PubMed ID: 17108835
[TBL] [Abstract][Full Text] [Related]
46. Effectiveness and safety of recombinant human bone morphogenetic protein-2 versus local bone graft in primary lumbar interbody fusions.
Adams CL; Ogden K; Robertson IK; Broadhurst S; Edis D
Spine (Phila Pa 1976); 2014 Jan; 39(2):164-71. PubMed ID: 24153173
[TBL] [Abstract][Full Text] [Related]
47. Symptomatic ectopic intracanal ossification after transforaminal lumbar interbody fusion with rhBMP-2.
Lehman RA; Kang DG
Spine J; 2012 Jun; 12(6):530-1. PubMed ID: 22682741
[No Abstract] [Full Text] [Related]
48. Accelerating lumbar fusions by combining rhBMP-2 with allograft bone: a prospective analysis of interbody fusion rates and clinical outcomes.
Slosar PJ; Josey R; Reynolds J
Spine J; 2007; 7(3):301-7. PubMed ID: 17482113
[TBL] [Abstract][Full Text] [Related]
49. Nerve injury and recovery after lateral lumbar interbody fusion with and without bone morphogenetic protein-2 augmentation: a cohort-controlled study.
Lykissas MG; Aichmair A; Sama AA; Hughes AP; Lebl DR; Cammisa FP; Girardi FP
Spine J; 2014 Feb; 14(2):217-24. PubMed ID: 24269858
[TBL] [Abstract][Full Text] [Related]
50. Complications associated with recombinant human bone morphogenetic protein use in pediatric craniocervical arthrodesis.
Lindley TE; Dahdaleh NS; Menezes AH; Abode-Iyamah KO
J Neurosurg Pediatr; 2011 May; 7(5):468-74. PubMed ID: 21529186
[TBL] [Abstract][Full Text] [Related]
51. Evaluation of the efficacy and safety of Escherichia coli-derived recombinant human bone morphogenetic protein-2 in transforaminal lumbar interbody fusion to treat degenerative spinal disease: a protocol of prospective, randomized controlled, assessor-blinded, open-label, multicenter trial.
Choi JY; Park HJ; Park SM; Kang CN; Song KS
J Orthop Surg Res; 2022 Aug; 17(1):397. PubMed ID: 36045371
[TBL] [Abstract][Full Text] [Related]
52. Vertebral osteolysis after posterior interbody lumbar fusion with recombinant human bone morphogenetic protein 2: a report of five cases.
Lewandrowski KU; Nanson C; Calderon R
Spine J; 2007; 7(5):609-14. PubMed ID: 17526434
[TBL] [Abstract][Full Text] [Related]
53. A prospective, randomized, controlled trial comparing radiographic and clinical outcomes between stand-alone lateral interbody lumbar fusion with either silicate calcium phosphate or rh-BMP2.
Pimenta L; Marchi L; Oliveira L; Coutinho E; Amaral R
J Neurol Surg A Cent Eur Neurosurg; 2013 Nov; 74(6):343-50. PubMed ID: 23444134
[TBL] [Abstract][Full Text] [Related]
54. Recombinant human bone morphogenetic protein-2 versus autogenous iliac crest bone graft for lumbar fusion: a meta-analysis of ten randomized controlled trials.
Chen Z; Ba G; Shen T; Fu Q
Arch Orthop Trauma Surg; 2012 Dec; 132(12):1725-40. PubMed ID: 22941273
[TBL] [Abstract][Full Text] [Related]
55. Complications and cancer rates in spine fusion with recombinant human bone morphogenetic protein-2 (rhBMP-2).
Vavken J; Mameghani A; Vavken P; Schaeren S
Eur Spine J; 2016 Dec; 25(12):3979-3989. PubMed ID: 25772092
[TBL] [Abstract][Full Text] [Related]
56. Analysis of prevertebral soft-tissue swelling and dysphagia in multilevel anterior cervical discectomy and fusion with recombinant human bone morphogenetic protein-2 in patients at risk for pseudarthrosis.
Stachniak JB; Diebner JD; Brunk ES; Speed SM
J Neurosurg Spine; 2011 Feb; 14(2):244-9. PubMed ID: 21184639
[TBL] [Abstract][Full Text] [Related]
57. Transforaminal lumbar interbody fusion with rhBMP-2 in spinal deformity, spondylolisthesis, and degenerative disease--part 1: Large series diagnosis related outcomes and complications with 2- to 9-year follow-up.
Crandall DG; Revella J; Patterson J; Huish E; Chang M; McLemore R
Spine (Phila Pa 1976); 2013 Jun; 38(13):1128-36. PubMed ID: 23370679
[TBL] [Abstract][Full Text] [Related]
58. Dose Adjustment Associated Complications of Bone Morphogenetic Protein: A Longitudinal Assessment.
De Stefano FA; Elarjani T; Burks JD; Burks SS; Levi AD
World Neurosurg; 2021 Dec; 156():e64-e71. PubMed ID: 34530148
[TBL] [Abstract][Full Text] [Related]
59. Interbody fusion with allograft and rhBMP-2 leads to consistent fusion but early subsidence.
Vaidya R; Weir R; Sethi A; Meisterling S; Hakeos W; Wybo CD
J Bone Joint Surg Br; 2007 Mar; 89(3):342-5. PubMed ID: 17356146
[TBL] [Abstract][Full Text] [Related]
60. Feasibility of Percutaneous Posterolateral Spinal Fusion With Recombinant Bone Morphogenetic Protein-2 (rhBMP-2): A Comparison With Standard Methods Using an Animal Model Study.
Chan CY; Kwan MK; Saw LB; Paisal H
Clin Spine Surg; 2017 Mar; 30(2):E138-E147. PubMed ID: 28207623
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
